A Decision Support Framework for Genomically Informed Investigational Cancer Therapy

Funda Meric-Bernstam, Amber Johnson, Vijaykumar Holla, Ann Marie Bailey, Lauren Brusco, Ken Chen, Mark Routbort, Keyur P. Patel, Jia Zeng, Scott Kopetz, Michael A. Davies, Sarina A. Piha-Paul, David S. Hong, Agda Karina Eterovic, Apostolia M. Tsimberidou, Russell Broaddus, Elmer V. Bernstam, Kenna R. Shaw, John Mendelsohn, Gordon Mills

Research output: Contribution to journalReview article

87 Citations (Scopus)

Abstract

Rapidly improving understanding of molecular oncology, emerging novel therapeutics, and increasingly available and affordable next-generation sequencing have created an opportunity for delivering genomically informed personalized cancer therapy. However, to implement genomically informed therapy requires that a clinician interpret the patient's molecular profile, including molecular characterization of the tumor and the patient's germline DNA. In this Commentary, we review existing data and tools for precision oncology and present a framework for reviewing the available biomedical literature on therapeutic implications of genomic alterations. Genomic alterations, including mutations, insertions/deletions, fusions, and copy number changes, need to be curated in terms of the likelihood that they alter the function of a "cancer gene" at the level of a specific variant in order to discriminate so-called "drivers" from "passengers." Alterations that are targetable either directly or indirectly with approved or investigational therapies are potentially "actionable." At this time, evidence linking predictive biomarkers to therapies is strong for only a few genomic markers in the context of specific cancer types. For these genomic alterations in other diseases and for other genomic alterations, the clinical data are either absent or insufficient to support routine clinical implementation of biomarker-based therapy. However, there is great interest in optimally matching patients to early-phase clinical trials. Thus, we need accessible, comprehensive, and frequently updated knowledge bases that describe genomic changes and their clinical implications, as well as continued education of clinicians and patients.

Original languageEnglish (US)
Article numberdjv098
JournalJournal of the National Cancer Institute
Volume107
Issue number7
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Investigational Therapies
Neoplasms
Therapeutics
Biomarkers
INDEL Mutation
Likelihood Functions
Knowledge Bases
Neoplasm Genes
Patient Education
Clinical Trials
DNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. / Meric-Bernstam, Funda; Johnson, Amber; Holla, Vijaykumar; Bailey, Ann Marie; Brusco, Lauren; Chen, Ken; Routbort, Mark; Patel, Keyur P.; Zeng, Jia; Kopetz, Scott; Davies, Michael A.; Piha-Paul, Sarina A.; Hong, David S.; Eterovic, Agda Karina; Tsimberidou, Apostolia M.; Broaddus, Russell; Bernstam, Elmer V.; Shaw, Kenna R.; Mendelsohn, John; Mills, Gordon.

In: Journal of the National Cancer Institute, Vol. 107, No. 7, djv098, 01.01.2015.

Research output: Contribution to journalReview article

Meric-Bernstam, F, Johnson, A, Holla, V, Bailey, AM, Brusco, L, Chen, K, Routbort, M, Patel, KP, Zeng, J, Kopetz, S, Davies, MA, Piha-Paul, SA, Hong, DS, Eterovic, AK, Tsimberidou, AM, Broaddus, R, Bernstam, EV, Shaw, KR, Mendelsohn, J & Mills, G 2015, 'A Decision Support Framework for Genomically Informed Investigational Cancer Therapy', Journal of the National Cancer Institute, vol. 107, no. 7, djv098. https://doi.org/10.1093/jnci/djv098
Meric-Bernstam, Funda ; Johnson, Amber ; Holla, Vijaykumar ; Bailey, Ann Marie ; Brusco, Lauren ; Chen, Ken ; Routbort, Mark ; Patel, Keyur P. ; Zeng, Jia ; Kopetz, Scott ; Davies, Michael A. ; Piha-Paul, Sarina A. ; Hong, David S. ; Eterovic, Agda Karina ; Tsimberidou, Apostolia M. ; Broaddus, Russell ; Bernstam, Elmer V. ; Shaw, Kenna R. ; Mendelsohn, John ; Mills, Gordon. / A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. In: Journal of the National Cancer Institute. 2015 ; Vol. 107, No. 7.
@article{b7f30c633ed44c46ba3bde59d4bf2114,
title = "A Decision Support Framework for Genomically Informed Investigational Cancer Therapy",
abstract = "Rapidly improving understanding of molecular oncology, emerging novel therapeutics, and increasingly available and affordable next-generation sequencing have created an opportunity for delivering genomically informed personalized cancer therapy. However, to implement genomically informed therapy requires that a clinician interpret the patient's molecular profile, including molecular characterization of the tumor and the patient's germline DNA. In this Commentary, we review existing data and tools for precision oncology and present a framework for reviewing the available biomedical literature on therapeutic implications of genomic alterations. Genomic alterations, including mutations, insertions/deletions, fusions, and copy number changes, need to be curated in terms of the likelihood that they alter the function of a {"}cancer gene{"} at the level of a specific variant in order to discriminate so-called {"}drivers{"} from {"}passengers.{"} Alterations that are targetable either directly or indirectly with approved or investigational therapies are potentially {"}actionable.{"} At this time, evidence linking predictive biomarkers to therapies is strong for only a few genomic markers in the context of specific cancer types. For these genomic alterations in other diseases and for other genomic alterations, the clinical data are either absent or insufficient to support routine clinical implementation of biomarker-based therapy. However, there is great interest in optimally matching patients to early-phase clinical trials. Thus, we need accessible, comprehensive, and frequently updated knowledge bases that describe genomic changes and their clinical implications, as well as continued education of clinicians and patients.",
author = "Funda Meric-Bernstam and Amber Johnson and Vijaykumar Holla and Bailey, {Ann Marie} and Lauren Brusco and Ken Chen and Mark Routbort and Patel, {Keyur P.} and Jia Zeng and Scott Kopetz and Davies, {Michael A.} and Piha-Paul, {Sarina A.} and Hong, {David S.} and Eterovic, {Agda Karina} and Tsimberidou, {Apostolia M.} and Russell Broaddus and Bernstam, {Elmer V.} and Shaw, {Kenna R.} and John Mendelsohn and Gordon Mills",
year = "2015",
month = "1",
day = "1",
doi = "10.1093/jnci/djv098",
language = "English (US)",
volume = "107",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - A Decision Support Framework for Genomically Informed Investigational Cancer Therapy

AU - Meric-Bernstam, Funda

AU - Johnson, Amber

AU - Holla, Vijaykumar

AU - Bailey, Ann Marie

AU - Brusco, Lauren

AU - Chen, Ken

AU - Routbort, Mark

AU - Patel, Keyur P.

AU - Zeng, Jia

AU - Kopetz, Scott

AU - Davies, Michael A.

AU - Piha-Paul, Sarina A.

AU - Hong, David S.

AU - Eterovic, Agda Karina

AU - Tsimberidou, Apostolia M.

AU - Broaddus, Russell

AU - Bernstam, Elmer V.

AU - Shaw, Kenna R.

AU - Mendelsohn, John

AU - Mills, Gordon

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Rapidly improving understanding of molecular oncology, emerging novel therapeutics, and increasingly available and affordable next-generation sequencing have created an opportunity for delivering genomically informed personalized cancer therapy. However, to implement genomically informed therapy requires that a clinician interpret the patient's molecular profile, including molecular characterization of the tumor and the patient's germline DNA. In this Commentary, we review existing data and tools for precision oncology and present a framework for reviewing the available biomedical literature on therapeutic implications of genomic alterations. Genomic alterations, including mutations, insertions/deletions, fusions, and copy number changes, need to be curated in terms of the likelihood that they alter the function of a "cancer gene" at the level of a specific variant in order to discriminate so-called "drivers" from "passengers." Alterations that are targetable either directly or indirectly with approved or investigational therapies are potentially "actionable." At this time, evidence linking predictive biomarkers to therapies is strong for only a few genomic markers in the context of specific cancer types. For these genomic alterations in other diseases and for other genomic alterations, the clinical data are either absent or insufficient to support routine clinical implementation of biomarker-based therapy. However, there is great interest in optimally matching patients to early-phase clinical trials. Thus, we need accessible, comprehensive, and frequently updated knowledge bases that describe genomic changes and their clinical implications, as well as continued education of clinicians and patients.

AB - Rapidly improving understanding of molecular oncology, emerging novel therapeutics, and increasingly available and affordable next-generation sequencing have created an opportunity for delivering genomically informed personalized cancer therapy. However, to implement genomically informed therapy requires that a clinician interpret the patient's molecular profile, including molecular characterization of the tumor and the patient's germline DNA. In this Commentary, we review existing data and tools for precision oncology and present a framework for reviewing the available biomedical literature on therapeutic implications of genomic alterations. Genomic alterations, including mutations, insertions/deletions, fusions, and copy number changes, need to be curated in terms of the likelihood that they alter the function of a "cancer gene" at the level of a specific variant in order to discriminate so-called "drivers" from "passengers." Alterations that are targetable either directly or indirectly with approved or investigational therapies are potentially "actionable." At this time, evidence linking predictive biomarkers to therapies is strong for only a few genomic markers in the context of specific cancer types. For these genomic alterations in other diseases and for other genomic alterations, the clinical data are either absent or insufficient to support routine clinical implementation of biomarker-based therapy. However, there is great interest in optimally matching patients to early-phase clinical trials. Thus, we need accessible, comprehensive, and frequently updated knowledge bases that describe genomic changes and their clinical implications, as well as continued education of clinicians and patients.

UR - http://www.scopus.com/inward/record.url?scp=84938209813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938209813&partnerID=8YFLogxK

U2 - 10.1093/jnci/djv098

DO - 10.1093/jnci/djv098

M3 - Review article

VL - 107

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7

M1 - djv098

ER -